Clindamycin HCl 22.7 mg/Clotrimazole 100 mg vaginal suppositories are a compounded medication designed to treat vaginal infections caused by both bacterial and fungal organisms. Clindamycin hydrochloride is a lincosamide antibiotic effective against anaerobic bacteria and certain gram-positive cocci. It works by inhibiting bacterial protein synthesis, thereby stopping the growth of bacteria. Clotrimazole is an antifungal agent that disrupts the cell membrane of fungi, leading to cell death and the resolution of fungal infections.

This combination therapy is particularly beneficial for patients experiencing mixed infections, such as bacterial vaginosis alongside vulvovaginal candidiasis. By addressing both types of pathogens simultaneously, the medication can provide comprehensive relief and reduce the duration of symptoms. The suppository form ensures that the active ingredients are delivered directly to the site of infection, enhancing efficacy and minimizing systemic side effects.

For patients using this medication, it is important to follow your healthcare provider's instructions carefully. Typically, the suppository is inserted into the vagina once daily, preferably at bedtime to allow for prolonged contact with the vaginal tissue. Before insertion, wash your hands thoroughly and, if applicable, remove the suppository from its packaging. Insert it gently into the vagina as far as it will comfortably go. Continue using the medication for the full prescribed duration, even if symptoms improve earlier, to ensure complete eradication of the infection.

Possible side effects may include mild irritation, itching, or burning at the application site. Some patients may experience gastrointestinal symptoms such as nausea or abdominal discomfort due to systemic absorption of clindamycin. If side effects are severe or persist, consult your healthcare provider promptly. It is also advisable to avoid sexual intercourse during treatment to prevent irritation and transmission of the infection.

For prescribers, this compounded formulation offers a targeted approach to managing complex vaginal infections. The combination of clindamycin and clotrimazole addresses both bacterial and fungal pathogens, potentially reducing the need for multiple medications and improving patient adherence. When prescribing this medication, consider the patient's medical history, including any allergies to lincosamide antibiotics or azole antifungals. Monitor for signs of clindamycin-associated colitis, such as severe diarrhea, and advise patients to report such symptoms immediately.

This formulation can be particularly useful in cases where standard treatments have failed or when infections are recurrent. Custom compounding allows for adjustments in dosing and excipients, catering to individual patient needs and sensitivities. Collaborative communication with the pharmacy can ensure optimal therapeutic outcomes.

If you have any questions, reach out to us.

Clindamycin HCl 22.7 mg/Clotrimazole 100 mg vaginal suppositories are used to treat bacterial and fungal infections in the vaginal area. Clindamycin is an antibiotic that works by inhibiting bacterial protein synthesis, thereby stopping bacterial growth. Clotrimazole is an antifungal agent that disrupts the cell membrane of fungi, leading to cell death. This combination is effective in treating mixed infections where both bacterial and fungal pathogens are present.

When using Clindamycin HCl/Clotrimazole vaginal suppositories, it is important to be aware of potential drug interactions that could affect the efficacy and safety of the treatment. Clindamycin, being a lincosamide antibiotic, may interact with other medications that affect the gut flora, such as oral contraceptives. The use of clindamycin can potentially reduce the effectiveness of hormonal contraceptives, leading to an increased risk of unintended pregnancy. Patients should be advised to use additional non-hormonal contraceptive methods during treatment and for a short period after completing the course.

Clotrimazole, as an azole antifungal, may interact with other medications metabolized by the cytochrome P450 enzyme system, particularly CYP3A4. Although systemic absorption of clotrimazole from vaginal suppositories is minimal, caution is advised when used concurrently with medications that are strong inhibitors or inducers of CYP3A4, as they may alter the plasma concentrations of clotrimazole. This is particularly relevant for patients on medications such as certain statins, anticoagulants, or immunosuppressants.

Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and supplements, to assess for potential interactions. Additionally, alcohol consumption should be minimized during treatment, as it may exacerbate side effects or reduce the effectiveness of the medication.

For prescribers, it is crucial to review the patient's medication history and consider any potential interactions that may arise from the use of Clindamycin HCl/Clotrimazole vaginal suppositories. Monitoring for signs of reduced efficacy or increased side effects is recommended, and adjustments to the patient's medication regimen may be necessary to ensure optimal treatment outcomes.

If you have any questions or require further information regarding the use of Clindamycin HCl/Clotrimazole vaginal suppositories, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any concerns or inquiries you may have.

Clindamycin HCl 22.7 mg/Clotrimazole 100 mg vaginal suppositories are a compounded formulation designed to deliver targeted treatment for specific vaginal infections. This solid dosage form is inserted into the vagina, where it dissolves or melts, allowing the active ingredients to be released directly at the site of infection. This localized delivery system ensures that the medication is concentrated where it is most needed, enhancing its effectiveness while minimizing systemic absorption and potential side effects.

Clindamycin HCl is an antibiotic that works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby preventing the translocation steps in protein synthesis. This action effectively halts the growth of susceptible bacteria, making it particularly useful in treating bacterial vaginosis, a condition characterized by an overgrowth of certain bacteria in the vagina. By reducing the bacterial load, clindamycin helps restore the natural balance of flora in the vaginal environment.

Clotrimazole, on the other hand, is an antifungal agent that works by disrupting the cell membrane of fungi. It inhibits the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased membrane permeability and ultimately cell death. This makes clotrimazole effective in treating yeast infections, such as those caused by Candida species. By targeting the fungal cells directly, clotrimazole helps alleviate symptoms like itching, burning, and discharge associated with vaginal yeast infections.

The combination of clindamycin and clotrimazole in a single suppository provides a broad-spectrum approach to treating mixed infections, where both bacterial and fungal pathogens may be present. This dual-action formulation is particularly beneficial for patients experiencing symptoms of both bacterial vaginosis and yeast infections simultaneously. The suppository form ensures that the medication is delivered directly to the site of infection, providing rapid relief and promoting healing.

For prescribers, this compounded formulation offers a customizable treatment option that can be tailored to the specific needs of the patient. The dosage and combination of active ingredients can be adjusted based on the severity and type of infection, as well as the patient's medical history and any potential allergies. This flexibility allows for a more personalized approach to treatment, which can improve patient outcomes and satisfaction.

Patients using clindamycin HCl 22.7 mg/clotrimazole 100 mg vaginal suppositories should follow the prescribed instructions carefully to ensure optimal results. It is important to complete the full course of treatment, even if symptoms improve, to prevent recurrence of the infection. Patients should also be aware of potential side effects, such as local irritation or allergic reactions, and contact their healthcare provider if they experience any adverse effects.

If you have any questions about this formulation or its use, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need to ensure safe and effective treatment.

Clindamycin HCl 22.7 mg/Clotrimazole 100 mg vaginal suppositories are primarily used for the treatment of bacterial vaginosis and vaginal yeast infections. However, this formulation may have other potential uses due to the pharmacological properties of its active ingredients. Clindamycin, a lincosamide antibiotic, is effective against a variety of anaerobic bacteria and some protozoal infections. Clotrimazole, an antifungal agent, is effective against a broad spectrum of fungal pathogens. Together, these agents can be considered for off-label use in treating mixed infections where both bacterial and fungal pathogens are present, particularly in cases where standard treatments have failed or are contraindicated.

For patients experiencing recurrent or chronic infections, this combination may offer a dual-action approach, potentially reducing the need for multiple medications and improving adherence to treatment regimens. Additionally, in certain cases of pelvic inflammatory disease (PID) where mixed infections are suspected, this formulation might be considered as part of a broader treatment strategy, although it is not a first-line treatment for PID. It is important for prescribers to evaluate the specific microbial flora involved in the infection and consider culture and sensitivity testing to ensure the appropriateness of this treatment.

Furthermore, in immunocompromised patients, such as those undergoing chemotherapy or with HIV/AIDS, who are more susceptible to opportunistic infections, this formulation might be used prophylactically or therapeutically to manage or prevent infections in the vaginal area. However, such use should be carefully monitored by healthcare professionals to avoid resistance development and ensure patient safety.

As with any off-label use, it is crucial for prescribers to weigh the potential benefits against the risks and to discuss these with their patients. Patients should be informed about the possible side effects, such as local irritation or allergic reactions, and advised to report any adverse effects promptly. If you have any questions or need further information about this formulation, please reach out to us at Bayview Pharmacy.